AN OPEN-LABEL, ASCENDING-DOSE, FIRST-INHUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INTRAVENOUS INFUSIONS OF ATB200 ALONE AND ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH POMPE DISEASE